CereVasc today announced that it received an FDA investigational device exemption approval to begin a trial of the eShunt for normal pressure hydrocephalus. The Boston-based company can initiate its pilot trial of the eShunt system in patients with normal pressure hydrocephalus (NPH). The eShunt device offers a minimally invasive treatment with the potential to result in […]
cerevasc
CereVasc successfully performs first-in-human procedure with eShunt system
CereVasc announced today that it completed the first treatment with its eShunt system for treating communicating hydrocephalus (CH). Boston-based CereVasc touts the eShunt as the first minimally invasive cerebrospinal fluid shunt and delivery technology designed to avoid the need for invasive surgery and extended hospitalization associated with the current surgical treatment of hydrocephalus. The company […]
CereVasc closes $43.9m Series A
Hydrocephalus treatment developer CereVasc announced today that it closed an expanded Series A financing round, raising a total of $43.9 million. The Perceptive Xontogeny Venture (PXV) Fund and ATON Partners led the funding round, according to a news release. CereVasc intends to use the raised proceeds to support the first-in-human clinical trial for its eShunt […]
Sunrise Labs executes succession plan | Personnel Moves – April 5, 2018
Medical device and life science development group Sunrise Labs said this week that it completed its succession plan, with president Eric Soederberg acquiring the majority of shares in the company through a stock sale with founder and board chair Drew Sunstein. With the transaction, the Bedford, N.H.-based company said that it secured its planned ownership […]
